LEUVEN, Belgium, Sept. 15, 2014 (GLOBE NEWSWIRE) -- TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC's, in inflammatory and autoimmune diseases, announced today the list of conferences in which it will participate during the second half of 2014.
15-16 September Stem Cells & Regenerative Medicine Congress 2014, Boston, USA Participant: Claudia Jimenez, Senior Director Business Development
17 September
30 September-1 October
2-3 October
14th Large & Midcap Event, Paris, France Participant: Claudia D'Augusta, Chief Financial Officer
6-8 October
Stem Cell Meeting on the Mesa, California, USA Presenter: Eduardo Bravo, Chief Executive Officer
18-22 October
22nd United European Gastroenterology Week (UEGW) , Vienna, Austria Participant: Mary Carmen Diez, VP Medical Affairs and New Product Commercialisation
3-5 November
BIO-Europe 2014 , Frankfurt, Germany Participant: Claudia Jimenez, Senior Director Business Development
13 November
3rd Edition Belgian Biotech & Pharma Seminar , New York, USA Participant: Eduardo Bravo, Chief Executive Officer
13 November
2nd Annual EU Advanced Therapies Investor Day , London, UK Presenter: Claudia D'Augusta, Chief Financial Officer
14-19 November
2014 American College Of Rheumatology Annual meeting , Boston, USA Participant: Marie Paule Richard, Chief Medical Officer
27 November
Petercam 2014 Healthcare Event , Brussels, Belgium Participant: Eduardo Bravo, Chief Executive Officer
For more information:
Richard Simpson Senior Consultant, Comfi sprl
T: +32 494 578 278
richard@comfi.be
About TiGenix
TiGenix NV (Euronext Brussels: TIG) is an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, or donor-derived, expanded adipose-derived stem cells, known as eASCs, in inflammatory and autoimmune diseases. Two products from this technology platform are currently in clinical development. Cx601 is in Phase III for the treatment of complex perianal fistulas in Crohn's disease patients. Cx611 is in Phase IIb for early rheumatoid arthritis, and in Phase Ib for severe sepsis. TiGenix also developed ChondroCelect, an autologous cell therapy product for cartilage repair of the knee, which was the first Advanced Therapy Medicinal Product (ATMP) to be approved by the European Medicines Agency (EMA). From June 2014, the marketing and distribution rights of ChondroCelect have been exclusively licensed to Sobi for the European Union (except for Finland, where it is distributed by the Finnish Red Cross Blood Service), Norway, Russia, Switzerland and Turkey, and the countries of the Middle East and North Africa. TiGenix is headquartered in Leuven (Belgium) and has operations in Madrid (Spain). For more information, please visit www.tigenix.com
Forward-looking information
This document may contain forward-looking statements and estimates with respect to the anticipated future performance of TiGenix and the market in which it operates. Certain of these statements, forecasts and estimates can be recognised by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will" and "continue" and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond the Company's control. Therefore, actual results, the financial condition, performance or achievements of TiGenix, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this document. TiGenix disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in the Company's expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by Belgian law.
HUG#1855647
